Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI343 + Sintilimab + SOX for Perioperative Treatment of Gastric/GEJ Adenocarcinoma
NCT07483567Phase 2Recruiting
- Sponsor
- Innovent Biologics
- Start
- Apr 2026
- Primary completion
- Jun 2030
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of arcotatug tavatecan in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Innovent Biologics. Primary endpoints: Pathological complete response rate up to 4 years and Dose-limiting toxicity up to 4 years. Started Apr 2026; status: recruiting.
02
Drugs
arcotatug tavatecan
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07483567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07483567.